Leonteq Securities AG Boosts Position in Bristol Myers Squibb Company $BMY

Leonteq Securities AG raised its position in Bristol Myers Squibb Company (NYSE:BMY) by 85.2% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 112,665 shares of the biopharmaceutical company’s stock after purchasing an additional 51,831 shares during the period. Leonteq Securities AG’s holdings in Bristol Myers Squibb were worth $6,833,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Swiss RE Ltd. acquired a new stake in Bristol Myers Squibb in the 4th quarter valued at about $25,000. Physician Wealth Advisors Inc. increased its holdings in Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 202 shares in the last quarter. Darwin Wealth Management LLC acquired a new position in Bristol Myers Squibb during the second quarter worth about $25,000. Bayban purchased a new stake in shares of Bristol Myers Squibb in the fourth quarter valued at about $31,000. Finally, EQ Wealth Advisors LLC purchased a new stake in shares of Bristol Myers Squibb in the fourth quarter valued at about $32,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on BMY shares. HSBC raised their price objective on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a research note on Tuesday, March 17th. Citigroup reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a research note on Friday, May 1st. UBS Group reiterated a “buy” rating on shares of Bristol Myers Squibb in a report on Thursday, May 28th. Weiss Ratings reissued a “hold (c)” rating on shares of Bristol Myers Squibb in a research report on Monday, March 23rd. Finally, Cantor Fitzgerald boosted their price target on Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a “neutral” rating in a report on Wednesday, April 8th. Eight research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $61.31.

Bristol Myers Squibb Stock Performance

Shares of NYSE BMY opened at $58.05 on Friday. The company has a 50-day simple moving average of $56.92 and a 200-day simple moving average of $57.48. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28. The company has a market cap of $118.54 billion, a PE ratio of 16.31, a price-to-earnings-growth ratio of 0.16 and a beta of 0.23. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The business had revenue of $11.49 billion for the quarter, compared to the consensus estimate of $10.93 billion. During the same quarter in the prior year, the firm posted $1.80 earnings per share. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities analysts anticipate that Bristol Myers Squibb Company will post 6.32 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.3%. The ex-dividend date of this dividend is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 70.79%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.